The overall goal of the Solid Tumors Program is to advance basic bench discoveries within and across disease sites, and apply them to novel clinical trials for solid malignancies.
We seek to establish an environment in which there are seamless interactions among all stakeholders - research scientists from all relevant disciplines, clinicians, computational biologists, biostatisticians and patients – to promote discovery and implementation of advances in clinical care that are rooted in science and technology.
Many of our members meet regularly as part of working groups in brain, breast, lung, gastrointestinal, and genitourinary (urologic) cancers. The group also includes specialists in gynecologic, skin, head & neck, and endocrine cancers. The activities in different disease site cancers are linked by common approaches and shared group applications.
Our researchers and clinicians work closely with members of other research programs to help characterize basic molecular mechanisms of cancer development and progression and identify novel targets for therapy; to understand cancer metastasis and the role of the tumor microenvironment; to develop better preclinical models to test novel therapeutics; and to initiate clinical trials to validate new treatment approaches and technologies.
First clinical trial of new targeted molecular therapy in U.S. takes aim at incurable prostate cancer
They are using the small molecule Lutetium 177Lu-PSMA-617 to target prostate-specific membrane antigen (PSMA), a protein that is abundantly expressed in 85-90 percent of metastasized prostate cancers. It binds to PSMA and delivers precise radiation therapy intended to shrink the cancer — even in cases in which cells have yet to form a visible tumor. An interdisciplinary team of investigators from the Meyer Cancer Center has begun the first clinical trial in the U.S. that uses a radiopharmaceutical to treat men with progressive, metastasized prostate cancer that is no longer responding to hormonal therapy.